Burcin Altun Ozdemir
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Burcin Altun Ozdemir has a total of 8 co-authors. Here are the top co-authors by number of shared publications:
- Andrew Tsourkas
University of Pennsylvania
1 shared publication - Biang Jang
Department of Bioengineering, University of Pennsylvania, 210 S. 33rd Street, 240 Skirkanich Hall, Philadelphia, PA 19104, USA
1 shared publication - Elizabeth Higbee-Dempsey
Developmental Therapeutics Core, Northwestern University, Evanston, USA
1 shared publication - Fabiana Zappala
Department of Bioengineering, University of Pennsylvania, 210 S. 33rd Street, 240 Skirkanich Hall, Philadelphia, PA 19104, USA
1 shared publication Gabriela T. Rosado González
Gabriela T. Rosado González, Department of Chemistry, University of Puerto Rico, 14, 2534 Av. Universidad Ste. 1401, San Juan, 00925 Puerto Rico
1 shared publicationJoann Miller
Department of Radiation Oncology, Perelman School of Medicine, University of Pennsylvania, 3400 Civic Center Blvd, Philadelphia, PA 19104, USA
1 shared publication
Latest Publications
- Open Access
- 6 May 2022
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 8 (18) , eabn4613
Rapid, site-specific labeling of “off-the-shelf” and native serum autoantibodies with T cell–redirecting domains
Extensive antibody engineering and cloning is typically required to generate new bispecific antibodies. Made-to-order genes, advanced expression systems, and high-efficiency cloning can simplify and accelerate this process, but it still can take months before a functional product is realized. We developed a simple method to site-specifically and covalently attach a T cell–redirecting domain to any off-the-shelf, human immunoglobulin G (IgG) or native IgG isolated from serum. No antibody engineering, cloning, or knowledge of the antibody sequence is required. Bispecific antibodies are generated in just hours. By labeling antibodies isolated from tumor-bearing mice, including two syngeneic models, we generated T cell–redirecting autoantibodies (TRAAbs) that act as an effective therapeutic. TRAAbs preferentially bind tumor tissue over healthy tissue, indicating a previously unexplored therapeutic window. The use of autoantibodies to direct the tumor targeting of bispecific antibodies represents a new paradigm in personalized medicine that eliminates the need to identify tumor biomarkers.
- 6 May 2022
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 8 (18) , eabn4613
Open AccessRapid, site-specific labeling of “off-the-shelf” and native serum autoantibodies with T cell–redirecting domains
Extensive antibody engineering and cloning is typically required to generate new bispecific antibodies. Made-to-order genes, advanced expression systems, and high-efficiency cloning can simplify and accelerate this process, but it still can take months before a functional product is realized. We developed a simple method to site-specifically and covalently attach a T cell–redirecting domain to any off-the-shelf, human immunoglobulin G (IgG) or native IgG isolated from serum. No antibody engineering, cloning, or knowledge of the antibody sequence is required. Bispecific antibodies are generated in just hours. By labeling antibodies isolated from tumor-bearing mice, including two syngeneic models, we generated T cell–redirecting autoantibodies (TRAAbs) that act as an effective therapeutic. TRAAbs preferentially bind tumor tissue over healthy tissue, indicating a previously unexplored therapeutic window. The use of autoantibodies to direct the tumor targeting of bispecific antibodies represents a new paradigm in personalized medicine that eliminates the need to identify tumor biomarkers.